Applied DNA Sciences, Inc. (APDN)
Applied DNA Sciences, Inc. operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Stony Brook, NY, US. The stock last traded at $5.62, up 31.62% on the session, giving a market capitalisation of $7.3M. On trailing twelve-month figures it carries a trailing P/E of -0.05, a net margin of -4197.8%. Its beta of 0.13 implies it has historically moved less than the broad market.
Applied DNA Sciences, Inc. specializes in devising and marketing sophisticated DNA-centric technological solutions across diverse sectors. Its activities encompass nucleic acid-based in vitro diagnostics and the preclinical development and production of nucleic acid-based pharmaceuticals. Furthermore, the company offers robust solutions for bolstering supply chain security, combating counterfeiting, and preventing theft. Key offerings for product authenticity and supply chain integrity include SigNature molecular tags, which imbue products with forensic traceability and protection, thereby strengthening brand defense and supply chain resilience while aiding in criminal identification and prosecution. To facilitate real-time, field-based verification of these tags, they provide SigNify IF portable DNA readers along with corresponding SigNify consumable reagent test kits. The CertainT platform represents a holistic approach, integrating tagging, testing, and tracking capabilities, empowering manufacturers, brands, and trade organizations to substantiate their product claims with verifiable evidence. Within the diagnostic realm, the company produces the LineaTM COVID-19 Assay Kit, a PCR-based molecular diagnostic test. It also offers the safeCircle COVID-19 diagnostic kit, specifically designed to help curtail viral transmission within communal settings such as schools or workplaces. Additionally, Applied DNA Sciences delivers contract research and manufacturing services for the burgeoning nucleic acid-based therapeutic markets during their preclinical phases. This extends to providing contract research for clients involved in preclinical studies of RNA-based drugs and biologics. The company is also at the forefront of developing an innovative technology for the capture and identification of invasive circulating tumor cells, utilizing a proprietary functional assay to isolate live invasive tumor cells and their associated lymphocytes. Operating internationally, the firm maintains a significant footprint across the United States, Europe, and Asia. Founded in 1983, the organization was initially known as Datalink Systems, Inc., before officially changing its name to Applied DNA Sciences, Inc. in 2002. Its corporate headquarters are located in Stony Brook, New York.
Applied DNA Sciences, Inc. is most often compared with the following Healthcare names: